Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL.
Eustace AJ, Conlon NT, McDermott MSJ, Browne BC, O'Leary P, Holmes FA, Espina V, Liotta LA, O'Shaughnessy J, Gallagher C, O'Driscoll L, Rani S, Madden SF, O'Brien NA, Ginther C, Slamon D, Walsh N, Gallagher WM, Zagozdzon R, Watson WR, O'Donovan N, Crown J.
Eustace AJ, et al. Among authors: browne bc.
BMC Cancer. 2018 Oct 11;18(1):965. doi: 10.1186/s12885-018-4852-1.
BMC Cancer. 2018.
PMID: 30305055
Free PMC article.